Madrigal Pharmaceuticals (NASDAQ: MDGL) insider files to sell 1,577 shares

Rhea-AI Filing Summary

Madrigal Pharmaceuticals insider plans stock sale under Rule 144. A person associated with Madrigal Pharmaceuticals, Inc. (MDGL) has filed a notice of intent to sell 1,577 shares of common stock through Morgan Stanley Smith Barney LLC on or about 01/26/2026 on the Nasdaq Stock Market. The filing lists an aggregate market value of 757,669.65 for these shares and notes that 22,711,420 shares of the company’s common stock were outstanding.

The 1,577 shares to be sold were acquired on 01/23/2026 through a restricted stock unit grant from the issuer that vested on the same date. The notice also reports that over the prior three months, William John Sibold, at the company’s address, sold 2,400 shares of common stock on 12/04/2025 for gross proceeds of 1,380,816.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza, 8th Floor New York NY 10004	1577	757669.65	22711420	01/26/2026	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/23/2026	Restricted Stock Unit Grant	Issuer			1577	01/23/2026	Vesting of Restricted Stock Units

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
William John Sibold c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	12/04/2025	2400	1380816

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Madrigal Pharmaceuticals (MDGL) disclose in this Form 144 filing?

The filing discloses an intended sale of 1,577 shares of Madrigal Pharmaceuticals common stock under SEC Rule 144, along with details on how the shares were acquired and prior sales over the last three months.

How many Madrigal Pharmaceuticals (MDGL) shares are planned to be sold and through which broker?

The notice covers an intended sale of 1,577 shares of common stock to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on the Nasdaq Stock Market.

What is the reported market value of the MDGL shares covered by this Form 144?

The 1,577 shares of Madrigal Pharmaceuticals common stock listed in the notice have a reported aggregate market value of 757,669.65.

When were the Madrigal Pharmaceuticals (MDGL) shares to be sold acquired, and how?

The 1,577 shares were acquired on 01/23/2026 via a restricted stock unit grant from the issuer, with the nature of payment described as vesting of restricted stock units on the same date.

What prior MDGL stock sales are reported for the past three months in this Form 144?

The document reports that William John Sibold, at the company’s address, sold 2,400 shares of common stock on 12/04/2025 for gross proceeds of 1,380,816.

How many Madrigal Pharmaceuticals (MDGL) shares are stated as outstanding in the Form 144?

The notice states that 22,711,420 shares of Madrigal Pharmaceuticals common stock were outstanding.

What representation does the selling person make in the Form 144 for MDGL?

The person for whose account the securities are to be sold represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.